Abstract: A tissue-removing catheter for removing tissue in a body lumen includes an elongate body and a tissue-removing element mounted on a distal end portion of the elongate body. The tissue-removing element is configured to remove the tissue as the tissue-removing element is rotated by the elongate body within the body lumen. An inner liner is received within the elongate body. The inner liner defines a guidewire lumen. The inner liner isolates an interior of the guidewire lumen from the elongate body and tissue-removing element such that rotational forces are not transferred from the elongate body and tissue-removing element to the interior of the guidewire lumen when the elongate body and tissue-removing element are rotated during removal of tissue from the body lumen.

Abstract: A system including one or more processors is provided. The one or more processors can receive data regarding charging sessions of electric vehicles at a plurality of chargers. The one or more processors can generate a score for each of the plurality of chargers based at least on the data regarding the charging sessions. The one or more processors can generate a path from a current location of a vehicle to a destination that includes a location for each of at least one of the plurality of chargers selected at least based on the scores. The one or more processors can update a user interface to depict the path including the location for each of the at least one of the plurality of chargers.

Abstract: Techniques are described herein that are capable of registering a user device with a cloud-based management service using an intermediate cloud storage. For instance, the intermediate cloud storage may store an encrypted data blob including information that identifies the user device. The intermediate cloud storage or a registration system may decrypt the encrypted data blob so that the registration system may use the decrypted data blob to register the user device with the cloud-based management service. For instance, the registration system may retrieve the encrypted or decrypted data blob from the intermediate cloud storage by providing a requisite secret to the intermediate cloud storage. The requisite secret may be provided to the registration system by the user device (e.g., via a matrix barcode, such as a QR code).

Abstract: The invention relates to vaccine compositions for inducing an immune response to a coronavirus in a subject, and uses thereof. In particular, the vaccine comprises of a chimeric or fusion protein comprising a) a N-terminal secretion signal peptide; b) an amino acid sequence of the receptor binding domain (RBD) of a spike protein of a coronavirus; and c) a C-terminal domain comprising a transmembrane region and a cytoplasmic region. In a preferred embodiment, the signal peptide, RBD, transmembrane region, and cytoplasmic region are derived from SARS-CoV-2, and that the vaccine composition is formulated as a lipid nanoparticle (LNP).

Abstract: A system leverages machine learning models to generate images, to customize and modify such images, and to generate additional images. The images can be generated within a digital canvas, allowing users to create sets of images, to compare such images, and to use such generated images to generate prompts and additional images. Tools can be provided to allow users to generate images with specific characteristics. For instance a color palette tool can allow users to specify particular colors and color shades for use in generating images. Likewise, a collage tool can allow users to generate and use a seed image to generate images for a collage of images. The system tracks states of images and other media content to promote user interaction with existing media content to generate new media content.

Abstract: A system leverages machine learning models to generate images, to customize and modify such images, and to generate additional images. The images can be generated within a digital canvas, allowing users to create sets of images, to compare such images, and to use such generated images to generate prompts and additional images. Tools can be provided to allow users to generate images with specific characteristics. For instance a color palette tool can allow users to specify particular colors and color shades for use in generating images. Likewise, a collage tool can allow users to generate and use a seed image to generate images for a collage of images. The system tracks states of images and other media content to promote user interaction with existing media content to generate new media content.

Abstract: A system leverages machine learning models to generate images, to customize and modify such images, and to generate additional images. The images can be generated within a digital canvas, allowing users to create sets of images, to compare such images, and to use such generated images to generate prompts and additional images. Tools can be provided to allow users to generate images with specific characteristics. For instance a color palette tool can allow users to specify particular colors and color shades for use in generating images. Likewise, a collage tool can allow users to generate and use a seed image to generate images for a collage of images. The system tracks states of images and other media content to promote user interaction with existing media content to generate new media content.

Abstract: This invention relates to berberine alkaloids, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals, particularly Lawsonia infection. In particular, the invention relates to berberine alkaloids, formulations thereof, and their application as antimicrobial agents in the prevention and/or treatment of infectious disease including bacterial, viral, parasitic or fungal infections, and for improving feed conversion ratio in food-producing animals. Also described is the use of berberine alkaloids as feed preservatives, added to feed compositions, and used in combination with further agents suitable for treating infectious disease.

Abstract: A method for timing path analysis using flow graphs. The method includes receiving timing data associated with an integrated circuit (IC) design. The timing data includes a plurality of timing paths. The method also includes generating a graphical representation of the plurality of timing paths. A timing path is represented as a flow ribbon across one or more components of the IC design. A display attribute of the flow ribbon is indicative of a metric of the timing path. The graphical representation is provided in a graphical user interface (GUI) to a user.

Abstract: Dynamic trip planning via a vehicle interface is provided. A system identifies a drive route for a vehicle. The drive route includes a first charger at a first location along the drive route configured to charge a battery of the vehicle. The system receives, via a communication session established with a mobile device, a command. The command is to add a stop to the drive route at a second location. The system determines, responsive to the command to add the stop at the second location, that the second location is within a threshold distance of a second charger configured to charge the battery of the vehicle. The system updates, based on a comparison of the first location with the second location, the drive route to add the second charger at the second location and remove the first charger at the first location.

Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.

Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.

Abstract: Dynamic route generation and charger discovery is provided. A system identifies a drive route for a vehicle. The drive route includes a first charger at a first location along the drive route configured to charge a battery of the vehicle. The system receives an indication of an amount of power output by the battery of the vehicle and an indication of a speed of the vehicle as the vehicle traverses the drive route. The system receives the indication via a battery management system of the vehicle. The system predicts, via a model trained with machine learning, a characteristic of the vehicle based on the amount of power and the speed. The system updates, responsive to the characteristic predicted via the model based on the amount of power and the speed, the drive route to include a second charger at a second location to charge the battery of the vehicle.

Abstract: The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.

Abstract: A tissue-removing catheter for removing tissue in a body lumen includes an elongate body and a tissue-removing element mounted on a distal end portion of the elongate body. The tissue-removing element is configured to remove the tissue as the tissue-removing element is rotated by the elongate body within the body lumen. An inner liner is received within the elongate body. The inner liner defines a guidewire lumen. The inner liner isolates an interior of the guidewire lumen from the elongate body and tissue-removing element such that rotational forces are not transferred from the elongate body and tissue-removing element to the interior of the guidewire lumen when the elongate body and tissue-removing element are rotated during removal of tissue from the body lumen.

Abstract: This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease in animals.

Abstract: A tissue-removing catheter for removing tissue in a body lumen includes an elongate body and a tissue-removing element mounted on a distal end portion of the elongate body. The tissue-removing element is configured to remove the tissue as the tissue-removing element is rotated by the elongate body within the body lumen. An inner liner is received within the elongate body. The inner liner defines a guidewire lumen. The inner liner isolates an interior of the guidewire lumen from the elongate body and tissue-removing element such that rotational forces are not transferred from the elongate body and tissue-removing element to the interior of the guidewire lumen when the elongate body and tissue-removing element are rotated during removal of tissue from the body lumen.

Abstract: A tissue-removing catheter for removing tissue in a body lumen includes a tube extending axially along the catheter. A junction box housing is located at a distal end of the tube. An elongate body extends distally from the junction box housing. The elongate body is sized and shaped to be received in the body lumen. A gear assembly is disposed in the junction box housing. The gear assembly engages the elongate body for rotating the elongate body. A tissue-removing element is mounted on a distal end portion of the elongate body. The tissue-removing element is configured to remove the tissue as the tissue-removing element is rotated by the elongate body within the body lumen.

Abstract: A tissue-removing catheter for removing tissue in a body lumen includes an elongate body having an axis, and proximal and distal end portions spaced apart from one another along the axis. The elongate body is sized and shaped to be received in the body lumen. A tissue-removing element is mounted on the distal end portion of the elongate body. The tissue-removing element is configured to remove the tissue as the tissue-removing element is rotated by the elongate body within the body lumen. An inner liner is received within the elongate body and defines a guidewire lumen. The inner liner is coupled to the tissue-removing element at a distal end portion of the inner liner. A coupling assembly is disposed in the tissue-removing element for coupling the inner liner to the tissue-removing element. The coupling assembly includes a bushing attached directly to the distal end portion of the inner liner.

Abstract: This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease, especially disease caused by C. perfringens and Eimeria in animals. The invention also relates to improving the feed conversion ratio in a food producing animal by administering berberine compositions.